关键信息
-
基因名
FANCC
- 应用
-
别名
bA80I15.1; FA 3; FA3; FAC; FACC; FANCC; FANCC_HUMAN; Fanconi anemia complementation group C; Fanconi anemia complementation group C protein; Fanconi anemia group C protein; Fanconi pancytopenia type 3; FLJ14675; Protein FACC
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q00597
-
表达区间
1-558aa
-
分子量
79.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
FGA, or fibrinogen alpha chain, is a key component of the fibrinogen protein complex, which plays a crucial role in blood coagulation and wound healing. Research into FGA recombinant proteins has gained significant attention due to their potential applications in medicine, particularly in tissue engineering and the development of hemostatic agents. The recombinant expression of FGA allows for the production of high-purity proteins that can be used to study the structure-function relationships of fibrinogen, its interactions with platelets, and the mechanisms underlying clot formation. Additionally, understanding FGA's role in various pathophysiological conditions, such as thrombosis and cardiovascular diseases, is vital for developing targeted therapies. Advances in genetic engineering and protein production techniques have facilitated the efficient synthesis of FGA, making it feasible to explore its therapeutic potential in treating bleeding disorders and improving surgical outcomes. Overall, the study of FGA recombinant proteins represents a promising area of research that bridges basic science and clinical applications, highlighting the importance of fibrinogen in both hemostasis and pathological states.
